Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2011. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share buyback activity.
- Shares Purchased: 1,100,000 Ordinary shares of 25 pence each.
- Purchase Date: June 22, 2011.
- Price Range: Highest price paid was 1,287.5 pence per share; lowest price paid was 1,267.5 pence per share.
- Treasury Holdings: Following cancellation, GSK holds 499,174,284 shares in Treasury.
- Treasury Percentage: Represents 8.85% of total issued share capital and 9.71% of total voting rights.
- Shares in Issue: 5,143,094,353 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the purchase and subsequent cancellation of 1,100,000 shares. This action increased the proportion of Treasury shares held by the Company relative to the total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding the share buyback.
Investor Verification Points
- Verify the total number of shares in issue (5,143,094,353) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (499,174,284) and its impact on voting rights (9.71%).
- Note that the purchased shares were cancelled, permanently reducing the Company's issued share capital.